ORIGINAL RESEARCH
Accepted on 11 Sep 2025
Addition of Bevacizumab to Gefitinib Plus Chemotherapy as First-line therapy in EGFR L858R mutate Advanced Non-Small Cell Lung Cancer Patients
doi 10.3389/fphar.2025.1503171
- 352 views
- Frontiers in Pharmacology
- Pharmacology of Anti-Cancer Drugs
- Research Topics
- Innovative Strategies for Overcoming Resistance in Tumor Angiogenesis Therapies
Innovative Strategies for Overcoming Resistance in Tumor Angiogenesis Therapies
2,598
Total downloads
11k
Total views and downloads
Articles
ORIGINAL RESEARCH
Published on 12 Aug 2025
KCTD10 inhibits lung cancer metastasis and angiogenesis via ubiquitin-mediated β-catenin degradation
doi 10.3389/fimmu.2025.1630311
- 1,406 views
SYSTEMATIC REVIEW
Published on 25 Jul 2025
Vasculogenic mimicry in non-small cell lung cancer: a systematic review
doi 10.3389/fonc.2025.1481726
- 1,285 views
ORIGINAL RESEARCH
Published on 23 Jul 2025
Emerging trends and knowledge networks in pan-cancer sorafenib resistance: a 20-year bibliometric investigation
doi 10.3389/fphar.2025.1581820
- 1,400 views
SYSTEMATIC REVIEW
Published on 30 May 2025
Efficacy and safety analyses of bevacizumab in neoadjuvant chemotherapy for ovarian cancer: a systematic review and meta-analysis
doi 10.3389/fphar.2025.1566604
- 1,339 views
SYSTEMATIC REVIEW
Published on 21 Nov 2024
Efficacy and safety of anti-angiogenic drugs combined with chemotherapy in the treatment of platinum-sensitive/resistant ovarian cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
doi 10.3389/fphar.2024.1446403
- 1,350 views
ORIGINAL RESEARCH
Published on 24 Jun 2024
A single-center, retrospective study-spring-evaluating the efficacy and safety of recombinant human vascular endothelial inhibitor combined with anti-PD-1 in elderly patients aged 80 and above with NSCLC
doi 10.3389/fimmu.2024.1402018
- 1,211 views
Published in
Frontiers in Pharmacology
Pharmacology of Anti-Cancer Drugs
Translational Pharmacology
Ethnopharmacology
Participating Journals
Frontiers in Oncology
- 3.3 impact factor
- 6.9 citescore